A recent headline in Politico Pulse pointed to a drug price transparency report from the state of Vermont that identified 10 prescription drugs that are “eating up state spending.” The top three drugs, Abilify, Lantus, and Humira, saw growth in wholesale acquisition costs over five years of 55%, 90%, and 114% respectively.
The report noted that while percentage increases in the price of generic drugs were higher, the actual dollar amounts were higher for name-brand drugs.
The top 10 drugs identified in the Vermont report are as follows:
- Abilify – an antipsychotic, for depression, bipolar disorder, and other conditions
- Lantus – name-brand insulin for treating diabetes
- Humira – an immunosuppressant for treating arthritis and Crohn’s Disease
- Enbrel – acts as TNF inhibitor to treat rheumatoid arthritis, among other diseases
- Crestor – a statin for treating high cholesterol
- Epipen – epinephrine for allergic attacks and asthma
- Latuda – an antipsychotic for treating schizophrenia
- Prevacid – a proton-pump inhibitor for treating acid reflux and heartburn
- Doxycycline Hyclate – an antibiotic for treating infections such as acne and gonorrhea
- Permethrin – an anti-parasite drug for treating lice and scabies
Among these, the Epipen has been in the headlines most recently for price hikes and a subsequent backlash against Epipen maker Mylan.
As health care costs–and especially pharma costs–continue to rise, awareness of which drugs are experiencing the largest price increases and which are most expensive is key to managing cost. Vermont’s experience with prescription drugs provides visibility into what is going on in other states and with health insurers and employers offering health insurance.
The issue is clearly on employers’ minds. According to Willis Towers Watson’s 21st annual Best Practices in Health Care Employer Survey, 88% of large employers identified managing pharmacy spending as a top priority in the next three years.
To read the entire report, click here.